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Since our first Report to the Nation, published in 1998, docu-
mented the first sustained decrease in cancer death rates since 
the 1930s (1), the American Cancer Society, the Centers for 
Disease Control and Prevention (CDC), the National Cancer 
Institute (NCI), and the North American Association of Central 
Cancer Registries (NAACCR) have collaborated annually to 
produce a report on the status of cancer in the United States. 
Each subsequent year, reports have updated information on 
trends in incidence and death rates and featured in-depth 
analyses of selected topics (2–12). The current report provides 
the latest information on trends for all cancers combined, childhood 
cancers, and for the top 15 cancers for each of the five major 
racial and ethnic groups by sex. Furthermore, this article pre-
sents a comprehensive assessment of the incidence of malignant 
and nonmalignant brain tumors in children and adults by race, 
sex, age group, and tumor histological type. National collection 
of nonmalignant brain tumors began in 2004 following the pas-
sage of Public Law 107-260, the Benign Brain Tumor Cancer 
Registries Amendment Act. The historical incidence, mortality, 
and survival by histological type, age, and era of diagnosis for 
malignant brain and other nervous system (ONS) tumors are 
presented.
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 Background The American Cancer Society, the Centers for Disease Control and Prevention (CDC), the National Cancer 
Institute, and the North American Association of Central Cancer Registries (NAACCR) collaborate annually to 
provide updated information on cancer occurrence and trends in the United States. This year’s report highlights 
brain and other nervous system (ONS) tumors, including nonmalignant brain tumors, which became reportable 
on a national level in 2004.
 Methods Cancer incidence data were obtained from the National Cancer Institute, CDC, and NAACCR, and information on 
deaths was obtained from the CDC’s National Center for Health Statistics. The annual percentage changes in 
age-standardized incidence and death rates (2000 US population standard) for all cancers combined and for the 
top 15 cancers for men and for women were estimated by joinpoint analysis of long-term (1992–2007 for inci-
dence; 1975–2007 for mortality) trends and short-term fixed interval (1998–2007) trends. Analyses of malignant 
neuroepithelial brain and ONS tumors were based on data from 1980–2007; data on nonmalignant tumors were 
available for 2004–2007. All statistical tests were two-sided.
 Results Overall cancer incidence rates decreased by approximately 1% per year; the decrease was statistically signifi-
cant (P < .05) in women, but not in men, because of a recent increase in prostate cancer incidence. The death 
rates continued to decrease for both sexes. Childhood cancer incidence rates continued to increase, whereas 
death rates continued to decrease. Lung cancer death rates decreased in women for the first time during 2003–
2007, more than a decade after decreasing in men. During 2004–2007, more than 213 500 primary brain and 
ONS tumors were diagnosed, and 35.8% were malignant. From 1987–2007, the incidence of neuroepithelial 
malignant brain and ONS tumors decreased by 0.4% per year in men and women combined.
 Conclusions The decrease in cancer incidence and mortality reflects progress in cancer prevention, early detection, and treat-
ment. However, major challenges remain, including increasing incidence rates and continued low survival for some 
cancers. Malignant and nonmalignant brain tumors demonstrate differing patterns of occurrence by sex, age, and 
race, and exhibit considerable biologic diversity. Inclusion of nonmalignant brain tumors in cancer registries pro-
vides a fuller assessment of disease burden and medical resource needs associated with these unique tumors.
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Subjects and Methods
Cancers, Cancer Deaths, and Population Estimates
Population-based cancer registries that are NAACCR members 
and participate in the NCI’s Surveillance, Epidemiology, and 
End Results (SEER) Program, and/or the CDC’s National 
Program of Cancer Registries were used to obtain information 
on newly diagnosed invasive cancers and benign and borderline 
brain tumors. Incident cases were classified by site and histology 
according to the International Classification of Diseases for Oncology 
(ICD-O) edition in use at the time of diagnosis, converted to the 
Third Edition coding (13) and categorized according to SEER 
site groups (14).
Incidence data were not available uniformly for every period, 
geographic area, and racial and ethnic group in the United States 
(Supplementary Table 1, available online). The longest continuous 
incidence data were available from the nine original SEER regis-
tries (SEER 9) covering about 10% of the US population. Long-
term (1975–2007) trends based on data from the SEER 9 registries 
are included in Supplementary Table 2 (available online). Data 
providing better coverage of the US population (about 14%) were 
available from the SEER 13 registries and form the basis of our 
long-term incidence trend (1992–2007) analysis for all races and 
ethnicities combined (15). Beginning in 1995, following the advent 
of the National Program of Cancer Registries, coverage of the US 
population increased dramatically. Data from NAACCR covering 
40 population-based cancer registries were used to assess short-term 
(1998–2007) trends. Data from 46 NAACCR population-based 
cancer registries were used to estimate 5-year (2003–2007) average 
annual age-standardized incidence rates for all races and ethnicities 
combined and for each of the five major racial and ethnic popula-
tions (white, black, Asian and Pacific Islander [API], American 
Indian/Alaska Native [AI/AN] who reside in counties covered by 
the Indian Health Service [IHS] Contract Health Service Delivery 
Area [CHSDA], and Hispanic). The 40 and 46 registries met 
NAACCR’s data quality criteria for every year included in the 
analysis; these registries covered 83.6% and 93% of the US popu-
lation, respectively.
All primary brain and ONS tumors (ICD-O-3 codes C70.0–72.9 
and C75.1–75.3, respectively), including malignant, borderline, 
and benign behaviors diagnosed in 2004–2007 were identified 
from 46 states in the NAACCR dataset. A neuropathologist 
reviewed the brain and ONS site and histology combinations and 
recommended excluding 1771 cases (0.8%) from analysis because 
of unlikely combinations. Consistent with the SEER site re-code 
convention, tumors coded to the nasal and nasopharyngeal regions 
also were excluded.
Data on approximately 76 000 malignant and 137 000 non-
malignant brain and ONS tumors were analyzed. Within the brain 
and ONS, seven major histological groups were used in analyses 
(16,17). Tumors of neuroepithelial tissue were divided into eight 
specific histological subgroups (16). Tumors of neuroepithelial 
tissue coded as nonmalignant by registries, but for which only a 
malignant behavior code existed in ICD-O-3, were considered 
malignant. Consistent with previous practice, pilocytic astrocy-
tomas were considered malignant. Malignant and papillary menin-
gioma and meningeal sarcomatosis were categorized as malignant, 
whereas all other benign and uncertain or atypical meningioma 
histologies were categorized as nonmalignant, according to the 
ICD-O-3 behavior codes. Childhood brain and ONS tumors also 
were grouped using International Classification of Childhood 
Cancers (ICCC) definitions (18).
Cause of death is based on death certificate information 
reported to state vital statistics offices and compiled into a national 
file through the CDC National Center for Health Statistics 
National Vital Statistics System (19) and categorized according to 
SEER anatomic site groups (14) to maximize comparability among 
ICD and ICD-O versions. The underlying causes of death were 
selected according to the version of the ICD codes and selection 
rules in use at the time of death (ICD-6 to ICD-10) (20–24). We 
examined long-term (1975–2007) mortality trends for all races and 
ethnicities combined. Short-term (1998–2007) trends and 5-year 
(2003–2007) average annual age-standardized death rates were 
calculated for all cancer sites combined and for the top 15 cancer 
sites for men and women in each of the five major racial and ethnic 
populations. Death rates for the AI/AN population were based on 
deaths in counties served by IHS CHSDA because estimated rates 
based on CHSDA counties have been reported to be more accu-
rate for this group (10,25).
County-level population estimates, summed to the state and 
national level, were used as denominators in calculations of inci-
dence rates (26). The National Center for Health Statistics and 
the Census Bureau collaborate to provide NCI with bridged 
single-race annual population estimates, with annual reestimates 
calculated back to the most recent decennial census to accommo-
date multiracial data (27). The NCI makes slight modifications to 
the Hawaii population estimates based on additional local infor-
mation (26).
For most states, population estimates as of July 1 of each year 
were used to calculate annual incidence and death rates. For 
Louisiana, Alabama, Mississippi, and Texas, where residents were 
displaced by Hurricanes Katrina and Rita, NCI made adjustments 
to the 2005 incidence data and underlying population data. The 
national total population estimates are not affected by these adjust-
ments (further details are available at http://seer.cancer.gov/popdata/
methods.html).
Statistical Analysis
Age-specific and age-standardized rates were expressed per 100 000 
persons (or per 1 000 000 children), based on 2000 US standard 
population, and generated using SEER*Stat Software, Version 
6.6.2 (http://www.seer.cancer.gov/seerstat) (28). Rates were 
suppressed if the numerator was less than 16 observations, consis-
tent with our previous work (1–12).
Trends in age-standardized cancer incidence and US death 
rates were analyzed using joinpoint regression, which involves 
fitting a series of joined straight lines on a logarithmic scale to the 
trends in the annual age-standardized rates (http://www.srab. 
cancer.gov/joinpoint). We allowed a maximum of three joinpoints 
in models for the period 1992–2007 (Table 1), four joinpoints in 
models for the period 1975–2007 (Table 2 and Supplementary 
Table 2, available online), and up to two joinpoints for the period 
1998–2007 for short-term fixed interval incidence (Table 3) and 
mortality analyses (Table 4). The joinpoint method is described in 
716   Special Article | JNCI Vol. 103, Issue 9  |  May 4, 2011
detail elsewhere (29). We present the long-term (1975–2007 and 
1992–2007) trends in incidence using annual percent changes 
(APCs; ie, the slope of the line segment) based on observed data 
and APCs adjusted for reporting delays (which affect mostly recent 
years). Delay-adjustment is a statistical method to correct for un-
reported (delayed) or updated cancer cases. Delay-adjusted APCs, 
used in our description of results, are available only for long-term 
incidence data (Table 1 and Supplementary Table 2, available 
online) (30). The average APC (AAPC), a summary measure to 
compare fixed interval trends by race and ethnicity, is estimated as 
a geometric weighted average of the joinpoint APC trend analysis, 
with the weights equal to the lengths of each segment during 
the prespecified fixed interval (http://srab.cancer.gov/joinpoint/
aapc.html) (31). The APC was suppressed if the numerator was 
less than 10 cancers for any year, consistent with our previous 
methods (1–12).
In describing long- and short-term trends with estimates of 
APC and AAPC, the terms “increase” or “decrease” signify that 
the slope (APC or AAPC) of the trend was statistically significant 
(P < .05) using a t test (APC) or Z test (AAPC). For non-statistically 
significant trends, we used terms such as “level,” “stable,” “non-
statistically significant increase,” or “non-statistically significant 
decrease.” All statistical tests were two-sided.
Results
Long-term Incidence Trends for All Races Combined, 
1992–2007
Trend analysis showed that overall cancer incidence rates for all 
racial and ethnic groups combined decreased by 0.8% per year 
during the most recent period, 2003–2007 (Table 1); a statistically 
significant decrease of 0.6% per year was noted in women, whereas 
a non-statistically significant decrease of 0.8% per year was noted 
in men that was influenced by a recent (2005–2007) non-statistically 
significant increase in prostate cancer incidence. When prostate 
cancer was excluded from the trend analysis, there was a statisti-
cally significant decrease in cancer incidence for all sites combined 
(data not shown). Incidence for prostate and breast cancers, two 
of the most frequently diagnosed cancers, showed possible 
changing trends. Cancer of the prostate showed a non-statistically 
significant annual increase of 3.0% in 2005–2007, after a statisti-
cally significant decrease in 2001–2005. The trend analysis of 
breast cancer in women showed a decrease from 1999 until 
2007. However, inspection of the annual breast cancer incidence 
rates during this period (data not shown) revealed that, after a 
sharp decrease in rates in 2002–2003, the lower rates subsequently 
remained stable. The cancer rates among children (0–19 years of Q2
Table 1. Surveillance, Epidemiology, and End Results (SEER) cancer incidence rate trends with joinpoint analyses (up to three joinpoints 
allowed) for 1992–2007 for the top 15 cancers, by sex, for all races*
Sex/cancer site or type
Joinpoint analyses (1992–2007)†
Trend 1 Trend 2 Trend 3 Trend 4 AAPC‡
Years APC§ Years APC§ Years APC§ Years APC§ 1998–2007 2003–2007
All sites║          
 Both sexes 1992–1994 23.2¶ 1994–1999 0.4 1999–2007 21.0¶   20.8# 21.0#
  Delay adjusted 1992–1994 23.1¶ 1994–1999 0.4 1999–2007 20.8¶   20.7# 20.8#
 Men 1992–1995 24.5¶ 1995–2000 0.2 2000–2007 21.4¶   21.1# 21.4#
  Delay adjusted 1992–1995 24.4¶ 1995–2001 0.1 2001–2005 21.9¶ 2005–2007 0.3 20.7# 20.8
 Women 1992–1998 0.8¶ 1998–2007 20.8¶     20.8# 20.8#
  Delay adjusted 1992–1998 0.8¶ 1998–2007 20.6¶     20.6# 20.6#
 Children (age 0–14 y) 1992–2007 0.4       0.4 0.4
  Delay adjusted 1992–2007 0.5       0.5# 0.5#
 Children (age 0–19 y) 1992–2007 0.5¶       0.5# 0.5#
  Delay adjusted 1992–2007 0.6¶       0.6# 0.6#
Top 15 cancers for men**          
 Prostate 1992–1995 211¶ 1995–2001 1.8¶ 2001–2005 24.3¶ 2005–2007 2.2 20.9 21.1
  Delay adjusted 1992–1995 211¶ 1995–2001 1.8¶ 2001–2005 24.2¶ 2005–2007 3.0 20.6 20.6
 Lung and bronchus 1992–2007 22.1¶       22.1# 22.1#
  Delay adjusted 1992–2007 22¶       22.0# 22.0#
 Colon and rectum 1992–1995 22.7¶ 1995–1998 1.7 1998–2007 23.0¶   23.0# 23.0#
  Delay adjusted 1992–1995 22.6¶ 1995–1998 1.7 1998–2007 22.9¶   22.9# 22.9#
 Urinary bladder 1992–2007 20.2       20.2 20.2
  Delay adjusted 1992–2007 20.1       20.1 20.1
 Non-Hodgkin lymphoma 1992–2007 20.1       20.1 20.1
  Delay adjusted 1992–2007 0.0       0.0 0.0
 Melanoma of the skin 1992–2007 2.2¶       2.2# 2.2#
  Delay adjusted 1992–2007 2.4¶       2.4# 2.4#
 Kidney and renal pelvis 1992–2007 1.9¶       1.9# 1.9#
  Delay adjusted 1992–2007 2.0¶       2.0# 2.0#
 Oral cavity and pharynx 1992–2007 21.5¶       21.5# 21.5#
  Delay adjusted 1992–2007 21.4¶       21.4# 21.4#
 Leukemia 1992–2007 20.6¶       20.6# 20.6#
  Delay adjusted 1992–2007 0.1       0.1 0.1
(Table continues)
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Sex/cancer site or type
Joinpoint analyses (1992–2007)†
Trend 1 Trend 2 Trend 3 Trend 4 AAPC‡
Years APC§ Years APC§ Years APC§ Years APC§ 1998–2007 2003–2007
 Pancreas 1992–2007 0.2       0.2# 0.2#
  Delay adjusted 1992–2003 0.0 2003–2007 1.9¶     0.8# 1.9#
 Stomach 1992–2007 21.9¶       21.9# 21.9#
  Delay adjusted 1992–2007 21.9¶       21.9# 21.9#
 Liver and intrahepatic  
  bile duct
1992–2007 3.2¶       3.2# 3.2#
  Delay adjusted 1992–2007 3.4¶       3.4# 3.4#
 Esophagus 1992–2007 20.1       20.1 20.1
  Delay adjusted 1992–2007 0.0       0.0 0.0
 Brain and other nervous  
  system
1992–2007 20.6¶       20.6# 20.6#
  Delay adjusted 1992–2007 20.4¶       20.4# 20.4#
 Myeloma 1992–2007 20.2       20.2 20.2
  Delay adjusted 1992–2007 0.2       0.2 0.2
Top 15 cancers for  
  women**
         
 Breast 1992–1999 1.1¶ 1999–2007 21.8¶     21.5# 21.8#
  Delay adjusted 1992–1999 1.1¶ 1999–2007 21.8¶     21.4# 21.8#
 Lung and bronchus 1992–1998 0.6 1998–2007 20.6¶     20.6# 20.6#
  Delay adjusted 1992–1997 0.7 1997–2007 20.3¶     20.3# 20.3#
 Colon and rectum 1992–1995 21.9¶ 1995–1998 2.0 1998–2007 22.3¶   22.3# 22.3#
  Delay adjusted 1992–1995 21.8¶ 1995–1998 2.0 1998–2007 22.2¶   22.2# 22.2#
 Corpus and uterus, NOS 1992–2007 20.3¶       20.3# 20.3#
  Delay adjusted 1992–2007 20.2¶       20.2# 20.2#
 Non-Hodgkin lymphoma 1992–2004 1.2¶ 2004–2007 21.8     0.2 21.1
  Delay adjusted 1992–2004 1.3¶ 2004–2007 21.2     0.4 20.6
 Thyroid 1992–1998 3.8¶ 1998–2007 6.4¶     6.4# 6.4#
  Delay adjusted 1992–1998 3.8¶ 1998–2007 6.6¶     6.6# 6.6#
 Melanoma of the skin 1992–1997 3.9¶ 1997–2007 1.5¶     1.5# 1.5#
  Delay adjusted 1992–2007 2.2¶       2.2# 2.2#
 Ovary║ 1992–2001 20.6¶ 2001–2007 22.0¶     21.5# 22.0#
  Delay adjusted║ 1992–1996 21.5 1996–2001 0.2 2001–2004 22.9 2004–2007 20.4 21.0 21.0
 Kidney and renal pelvis 1992–2007 2.3¶       2.3# 2.3#
  Delay adjusted 1992–1998 1.2 1998–2007 3.0¶     3.0# 3.0#
 Pancreas 1992–2007 0.4¶       0.4# 0.4#
  Delay adjusted 1992–2000 20.1 2000–2007 1.3¶     1.0# 1.3#
 Leukemia 1992–2007 20.3       20.3 20.3
  Delay adjusted 1992–2007 0.5¶       0.5# 0.5#
 Urinary bladder 1992–2004 20.2 2004–2007 22.7¶     21.0# 22.1#
  Delay adjusted 1992–2004 20.2 2004–2007 22.2     20.9# 21.7#
 Cervix uteri 1992–2007 22.9¶       22.9# 22.9#
  Delay adjusted 1992–2007 22.8¶       22.8# 22.8#
 Oral cavity and pharynx 1992–2007 21.2¶       21.2# 21.2#
  Delay adjusted 1992–2007 21.1¶       21.1# 21.1#
 Brain and other nervous  
  system
1992–2007 20.2       20.2 20.2
  Delay adjusted 1992–2007 0.0       0.0 0.0
*  AAPC = average annual percent change; APC = annual percent change; NOS = not otherwise specified. Source: SEER-13 areas covering about 14% of the US 
population (Connecticut, Hawaii, Iowa, Utah, New Mexico, the Alaska Native Tumor Registry, rural Georgia, and the metropolitan areas of San Francisco, Los 
Angeles, San Jose-Monterey, Detroit, Atlanta, and Seattle-Puget Sound). Nonadjusted rates and rates that were adjusted for delays in reporting are shown.
† Joinpoint analyses with up to three joinpoints yielding up to four trend segments (Trend 1–Trend 4) were based on rates per 100 000 persons and were age 
standardized to the 2000 US standard population (19 age groups: <1, 1–4, 5–9, 10–14, . . . , 80–84, >85 years, Census P25-1130). Joinpoint analysis used the 
Joinpoint Regression Program, Version 3.4.3. April 2010, Surveillance Research Program, National Cancer Institute.
‡ AAPC is a weighted average of the APCs calculated by joinpoint.
§ APC is based on rates that were age standardized to the 2000 US standard population (19 age groups: <1, 1–4, 5–9, 10–14, . . . , 80–84, >85 years, Census 
P25–1130).
║ All sites exclude myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
¶ APC is statistically significantly different from zero (two-sided t test, P < .05).
# AAPC is statistically significantly different from zero (two-sided Z test, P < .05).
** The top 15 cancers were selected based on the sex-specific age-standardized incidence rates for 2003–2007 for all races combined and listed in rank order.
Table 1 (Continued).
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age) showed an increase of 0.6% per year for both the most recent 
5-year period (2003–2007) and the entire period (1992–2007).
During the period 2003–2007, incidence rates for five of the 15 
most common cancers among men demonstrated a statistically 
significant decrease: lung and bronchus (lung), colon and rectum 
(colorectal), oral cavity and pharynx (oral), stomach, and malignant 
brain tumors. Trends in four cancers among men (melanoma of 
the skin, kidney and renal pelvis [kidney], pancreas, and liver and 
intrahepatic bile duct [liver]) showed statistically significant in-
creases during the period 2003–2007, whereas trends for prostate, 
urinary bladder (bladder), and esophageal cancers and leukemia, 
myeloma, and non-Hodgkin lymphoma did not demonstrate a 
statistically significant increase or decrease. Among women, statis-
tically significant increasing trends were noted in three of the four 
cancers that were increasing in men (kidney, pancreas, melanoma 
of the skin); leukemia and thyroid cancer also increased. Statistically 
significant decreasing trends for women included cancers of the 
breast, lung, colon and rectum, corpus uteri (uterus), cervix uteri 
(cervix), bladder, and oral cavity. No statistically significant trends 
in non-Hodgkin lymphoma, malignant brain tumors, and cancer 
of the ovary were observed.
Long-term Mortality Trends for All Races Combined, 
1975–2007
Since the early 1990s, overall cancer death rates have shown a 
statistically significant decreasing trend among both men and 
women; whereas for children, cancer death rates have decreased 
since the mid-1970s (Table 2). Trends in death rates during the 
most recent 10- and 5-year periods (1998–2007 and 2003–2007) 
continued to decrease for seven of the top 15 cancer types in both 
men and women (colon and rectum, brain, stomach, and kidney 
cancers, and non-Hodgkin lymphoma, leukemia, and myeloma); 
for cancers of the lung, prostate, and oral cavity in men; and for 
breast and bladder cancers in women. In contrast, during the cor-
responding time intervals, death rates from liver cancer and mela-
noma of the skin in men and those for liver and pancreatic cancers 
in women continued to exhibit statistically significant increases. 
Notably, lung cancer death rates in women revealed a statistically 
significant decrease during the period 2003–2007, following long-
term increases during the period 1975–2003, and cervical cancer 
death rates stabilized after decreasing for many decades. It also is 
noteworthy that long-term trends in death rates may mask impor-
tant changes during the shorter term. For example, the 10-year 
AAPC (1998–2007) for lung cancer in women showed a small non-
statistically significant decrease of 0.2% that was composed of a 
statistically significant increase of 0.3% from 1995 to 2003, fol-
lowed by a statistically significant decrease of 0.9% from 2003 to 
2007 (Table 2).
Cancer Incidence Rates, 2003–2007, and Short-term Fixed 
Interval Trends by Race and Ethnicity, 1998–2007
Black men had the highest cancer incidence rate for 2003–2007 of 
any racial and ethnic group (Table 3). Except among Hispanics, 
the top three cancer sites for men in each population group 
were, in rank order, prostate, lung, and colorectal cancers; among 
Hispanics, the colorectal cancer rate was slightly higher than the 
rate of lung cancer. Among women, white women had the highest 
overall incidence rates. Breast cancer was the most commonly 
diagnosed cancer among women regardless of race and ethnicity. 
Lung and colorectal cancers ranked second and third (respectively) 
among women of all races combined and for white, black, and AI/
AN women. However, these rankings were reversed among API 
and Hispanic women. For all populations, cancer of the uterus 
ranked fourth. Beyond the top three cancer sites for men and top 
four for women, cancer rankings varied by race and ethnicity.
Incidence rates for all cancer sites combined decreased between 
1998 and 2007 in both men and women in all populations; 
although the decrease was non-statistically significant among black 
or AI/AN women (Table 3). Childhood (ages 0–19 years) cancer 
incidence increased in all populations, although the increase was 
non-statistically significant for API and AI/AN children. Prostate 
cancer incidence showed a statistically significant decrease among 
AI/AN and Hispanic men. Breast cancer incidence rates decreased 
in all women, but the decrease was of smaller magnitude and non-
statistically significant for black and API women. Among men, 
lung cancer incidence rates decreased for all populations; among 
women, no statistically significant change was observed in any 
racial or ethnic group. Colorectal cancer rates decreased among 
both men and women in all population groups, but the decrease 
was non-statistically significant for AI/AN women. Cancer of the 
uterus increased among black, API, and Hispanic women but 
not among white women. Incidence rates of esophageal cancer 
increased among white men but decreased among blacks and 
Hispanics.
Cancer Death Rates, 2003–2007, and Short-term Trends by 
Race and Ethnicity, 1998–2007
Overall cancer death rates from 1998–2007 decreased for all race, 
ethnic, and sex groups except AI/AN women, among whom the 
decrease was non-statistically significant (Table 4). However, the 
largest average annual percentage decrease occurred in black and 
Hispanic men, approximately 2.5% per year. During the corre-
sponding time interval, overall cancer death rates also showed a 
statistically significant decrease of 1%–2% per year for children 
aged 0–19 years in each racial and ethnic group, except in 
Hispanics and AI/AN, in whom rates were stable. Similarly, death 
rates in each racial and ethnic group decreased for each of the 
three major cancers in men and women (lung, colorectal, prostate, 
or breast), except the trends for prostate and colon cancers among 
AI/AN men and for lung cancer among women of all racial groups 
were non-statistically significant. A statistically significant increase 
in liver cancer death rates was noted among white men and women 
and black and Hispanic men, whereas the increase in pancreatic 
cancer death rates was noted only in white men and women.
Brain and ONS Tumors
The distribution of malignant, benign, and borderline brain and 
ONS tumors during the period 2004–2007 is shown for adults in 
Table 5 and for children in Table 6. Nonmalignant tumors were 
about twice as common as malignant tumors among adults (aged 
≥20 years). Women had an overall brain tumor incidence rate of 
26.55 per 100 000 persons; men had a corresponding rate of 22.37. 
Tumors of neuroepithelial tissue were the most common histolog-
ical group of malignant brain tumor, occurring more frequently in 
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men than women. Glioblastoma, which occurred 1.6 times more 
frequently in men, was the most common subtype of neuroepithe-
lial tumor. The most common type of nonmalignant adult brain 
tumor was meningioma, which was 2.3 times more common in 
women than in men, with an incidence rate of 12.42 per 100 000 
vs 5.46 per 100 000 persons, respectively. The rate of meningioma 
in women was by far the highest incidence rate for any type of 
brain tumor in either sex. In contrast to neuroepithelial tumors, 
94.9% of which were malignant, only 2.1% of meningiomas were 
malignant.
Incidence rates among children aged 0–19 years were much 
lower than in adults (48.47 per 1 000 000 children vs 24.55 per 100 
000 adults), but the tumors were much more likely to be malignant 
in children: 65.2% vs 33.7% malignant in adults. Boys had only 
slightly more tumors of neuroepithelial tissue than girls (35.71 in 
boys vs 32.62 in girls per 1 000 000 children), yet adult men had 
incidence rates of neuroepithelial tumors 1.4 times higher than 
women. Tumors of the meninges were more likely to be malignant 
in children when compared with adults and occurred in boys and 
girls with similar frequency. Tumors of neuroepithelial tissue were 
more likely to be malignant in adults, whereas germ cell tumors 
were more likely to be malignant in children. Tumors of the nerve 
sheath were rarely malignant, and lymphomas of the brain were 
relatively rare in both adults and children.
Whites had the highest incidence rates of brain and ONS 
tumors (19.0 per 100 000 persons), followed by Hispanics (17.8 per 
100 000 persons) and blacks (17.7 per 100 000 persons) (Table 7). 
AI/ANs had lower incidence rates of brain and ONS tumors (15.3 
per 100 000 persons), and APIs had the lowest incidence rates 
(13.5 per 100 000 persons). Glioblastoma was the most common 
type of malignant brain tumor, with whites having the highest 
incidence rates, followed by Hispanics, blacks, and AI/ANs; with 
APIs having roughly one-half the rate of these tumors when com-
pared with whites. The two most common types of nonmalignant 
brain tumors were higher among blacks compared with whites. 
Meningioma was the most common brain tumor, with black 
women having the highest incidence rates overall (9.7 per 100 000 
persons), and black men having the highest incidence rates among 
men. Blacks and Hispanics had the highest incidence rates of 
tumors of the sellar region; however, acoustic neuromas occurred 
more than twice as often among whites compared with blacks.
Childhood brain and ONS tumor counts and incidence 
rates using ICCC-3 definitions are presented in Table 8. This 
classification system is used widely with childhood brain and ONS 
tumors but does not allow for comparison with adults. Childhood 
cancer incidence rates presented in Table 8 may differ from those 
presented elsewhere in this article because of the different 
classification systems used to produce the tables.
Childhood brain and ONS tumors demonstrate unique age-
specific incidence patterns by sex and type of tumor classification 
(Supplementary Table 3, available online). The incidence rate 
remained below six per 100 000 persons until age 25–29 years, 
after which the incidence increased steadily until age 84 years. By 
sex, incidence rates were higher in boys through age 10–14 years, 
after which the incidence rates became higher in women, primarily 
because of the large increase in meningiomas in this group 
(Supplementary Tables 4 and 5, available online). Incidence rates 
were higher in men or similar to women for all age groups for most 
tumors of neuroepithelial tissue, nerve sheath tumors, germ cell 
tumors, and lymphomas; however, women had a much higher 
incidence rate of meningioma than men, beginning with age group 
20–24 years. Incidence rates for tumors of the sellar region were 
higher in women until age 45–49 years; however, this pattern was 
reversed at 50 years and older. Acoustic neuromas began increasing 
from age 40 years, peaked at ages 65–69 years, after which the 
incidence rates decreased.
Trends of malignant neuroepithelial tumors by histological 
group are shown in Figure 1 and Supplementary Table 6 (available 
online). The incidence of these tumors in men and women com-
bined increased at a rate of 1.9% per year from 1980 to 1987 and 
decreased at a rate of 0.4% per year from 1987 to 2007, resulting 
in a minimal net change from 1980 to 2007. However, trends 
in incidence rates differed markedly among histological groups 
within this category. Marked changes in incidence rates for pri-
mary brain lymphomas also were observed (data not shown).
Relative survival (14) for brain and ONS tumors is strongly 
related to age at diagnosis, histological type, and era of diagnosis, 
as demonstrated in Figure 2. Five-year survival for all malignant 
tumors of neuroepithelial tissue as well as for most histological 
types and age groups has increased over time. Five-year survival 
among children and adolescents with all malignant tumors of 
neuroepithelial tissue combined increased from 62.9% for those 
diagnosed in 1980–1989 to 75.3% in 2000–2006 (Supplementary 
Table 7, available online). Favorable survival and trends also were 
observed for those aged 20–39 years, for whom 5-year survival 
increased from 54.1% in 1980–1989 to 65.1% in 2000–2006. 
However, among those diagnosed at age 40–64 years, survival 
increased from only 16.1% to 26.6%; among those diagnosed at 
age 65 years or older, the 5-year survival was under 5%, even in 
the most recent period (2003–2007). Among the most common 
tumors, the 5-year survival for pilocytic astrocytoma increased 
from 90.1% in 1980–1989 to 96.4% in 2000–2006 among children 
aged 0–19 years. Survival was nearly as high in those aged 20–39 
years and increased markedly in those aged 40 years or older, from 
46.1% in 1980–1989 to 83.5% in 2000–2006. In contrast, there 
was relatively little improvement in survival for astrocytomas 
during this time interval. Irregular trends and low survival for 
glioblastoma were observed in the two youngest age groups (0–19 
and 20–39 years), with 5-year survival exceeding 20% only in the 
most recent time period. In the two older age groups (40–64 
and ≥65 years), glioblastoma survival exceeded 5% at 5 years only 
in those aged 40–64 years diagnosed in 2000–2006. Five-year sur-
vival for oligodendroglioma and anaplastic oligodendroglioma in 
those aged 0–19 years increased from 70.2% to 90.8% in 2000–
2006. Survival of greater than 75% was observed for those aged 
20–39 years, in each time period. Although survival increased over 
time for those aged 40–64 years and those 65 years and older, it 
remained generally lower than in the younger age groups. In con-
trast, survival trends for neuroepithelial tumors in the grouping 
“embryonal, primitive, and medulloblastoma” differed by age 
group, with marked increases for those in the 0–19 and 20–39 year 
age ranges but marked decreases for those aged 40 years and older. 
Survival for malignant gliomas, not otherwise specified, showed 
greater improvement over time than for mixed gliomas.
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Figure 1. Trends in malignant neuroepithelial 
tumors in men and women by histology, 
1980–2007. Trends calculated using joinpoint 
analysis with up to four joinpoints on 
Surveillance, Epidemiology, and End Results 
9 registry data (Connecticut, Hawaii, Iowa, 
New Mexico, Utah; metropolitan areas of 
San Francisco, Detroit, Atlanta, Seattle-Puget 
Sound).
Death rates for malignant brain tumors during 1999–2007 
were stable in children (aged 0–19 years) but decreased in adults 
(aged ≥20 years) at a rate of 1.2% per year. Death rates for benign 
brain tumors decreased in both children (22.5% per year) and 
adults (22.2% per year). Trends in mortality for malignant vs non-
malignant brain tumors could not be examined for earlier time 
periods because of inconsistencies in ICD coding over time.
Discussion
This “Annual Report to the Nation” is the first to document a 
statistically significant decrease in lung cancer incidence and death 
rates among women from 2003 to 2007 (Tables 1 and 2), more 
than a decade after the rates began to decrease in men. Although 
cigarette smoking peaked in men who served in World War II and 
were born in the early 1920s, it peaked in women born in the late 
1930s (32,33). The decrease in lung cancer rates in women that we 
are seeing now reflects the later uptake of cigarette smoking 
among women. The decrease in lung cancer rates in women can be 
expected to continue for at least two decades as women in the older 
generations with higher lung cancer risk are replaced by the sub-
sequent younger generations with lower risk. But trends may be 
interrupted as women born around 1960, who have higher lung 
cancer and smoking rates, enter the high-risk age groups (11,34,35). 
In contrast to women, lung cancer rates in men are expected to 
continue to decrease in the subsequent younger generations (11).
In addition to lung cancer, death rates in the most recent period 
(2003–2007) showed a statistically significant decrease for seven of 
the remaining 14 leading cancers among both men and women 
(cancers of the colorectum, kidney, stomach, brain, leukemia, non-
Hodgkin lymphoma, and myeloma) as well as for prostate and oral 
cancer among men and cancers of the breast, ovary, and bladder 
among women. As a result, death rates from all cancers combined 
continued to decrease among both men and women and in all 
racial and ethnic groups, except among AI/AN women. These 
decreases indicate real progress in cancer control, reflecting a 
combination of primary prevention, early detection, and treatment 
(2–12). However, death rates continued to increase for cancers of 
the pancreas and liver among men and women, and for uterine 
cancer in women, cancers for which there are no established 
screening tests. Among men, death rates also increased for mela-
noma, for which population screening is not recommended but 
prevention and early detection strategies are available (36,37). 
Among children, long-term (1975–2007) trends in death rates 
continued to decrease, although at a slower pace during the recent 
decade than in earlier years.
The overall cancer incidence rates showed a statistically sig-
nificant decrease during the most recent period (2003–2007) in 
women, but the decrease was not statistically significant in men. 
These trends are driven largely by trends in the most common 
cancer sites (lung, colorectal, prostate, and female breast), ac-
counting for more than 50% of the overall rates in both men and 
women (38). Incidence rates decreased for cancers of the lung, 
colorectum, and oral cavity in both men and women; for breast, 
cervix, uterine, and bladder cancers in women; and for stomach 
and brain cancers in men. In contrast, incidence rates increased for 
kidney and pancreatic cancers and melanoma in both men and 
women, for liver cancer in men, and for thyroid cancer and leuke-
mia in women. Prostate cancer rates showed a non-statistically 
significant increase. Factors that contribute to these trends were 
discussed previously (4,7,8,11,12,34,35) and include changes in 
risk factors, screening modalities, and diagnostic practices.
Of the leading cancers, prostate cancer and breast cancer are of 
special note because they are the most frequently diagnosed cancers 
and second leading cause of cancer death among men and women, 
respectively. Prostate cancer incidence has fluctuated through the 
years, decreasing during 1992–1995, increasing during 1995–2001, 
decreasing during 2001–2005, and increasing again during 
2005–2007, albeit non-statistically significantly (Table 1). Prostate 
cancer death rates have decreased substantially over time (39), but the 
contribution of prostate-specific antigen screening to this decrease and 
the risks and benefits for individual men remain uncertain (40–44).
jnci.oxfordjournals.org   JNCI |  Special Article 731
Trends in breast cancer incidence over time reflect long-term 
changes in reproductive and other risk factors, introduction and 
prevalence of mammography screening, and use of hormones 
among postmenopausal women (45) (Table 1 and Supplementary 
Table 1, available online). Breast cancer incidence rates stabilized 
from 2003 to 2007 (46) after decreasing sharply between 2002 
and 2003, which was temporally associated with the dramatic 
decrease in the use of postmenopausal hormonal replacement 
therapy (47,48). The stabilization of the rates after the sharp 
decrease between 2002 and 2003 may in part reflect the role of 
hormonal replacement therapy as a promoting agent rather than 
as an initiating agent in the development of breast cancer 
(DeSantis et al., unpublished data). Meanwhile, breast cancer 
death rates continued to exhibit a statistically significant decrease. 
Mammography screening generally is accepted to reduce breast 
cancer mortality and has been recommended for some time, 
although recommendations have varied among organizations 
with respect to age at initiation for average risk women, screening 
intervals, and screening modalities, especially for high-risk 
women (49–55).
Of concern is the long-term increase in cancer incidence rates 
among children, which may be because of larger increases in inci-
dence rates for the lymphoid leukemias and proportionately 
smaller increases for other childhood cancers (56). Considerable 
progress has occurred for many types of childhood cancers, result-
ing in decreases in cancer death rates among children since 1975, 
although the rate of decrease has slowed since the mid-1990s. 
These decreases have resulted from refinements in treatment that 
substantially improved survival for many childhood cancers. 
However, for some types of childhood cancer, including some 
brain tumors, progress has been more modest and current treat-
ments remain inadequate (56).
Differences in rates and trends in incidence and death rates for 
specific cancers for different racial and ethnic groups and for men 
and women suggest differences in risk behaviors, socioeconomic 
status, and access to and use of screening and treatment (57,58). 
Figure 2. Five-year relative survival for 
neuroepithelial histologies (malignant) in 
men and women by age and time period. 
Relative survival calculated based on his-
tology, age at diagnosis, and decade of 
diagnosis using data from Surveillance, 
Epidemiology, and End Results 9 registries 
(Connecticut, Hawaii, Iowa, New Mexico, 
Utah; metropolitan areas of San Francisco, 
Detroit, Atlanta, Seattle-Puget Sound).
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It is particularly important to monitor these trends to identify 
opportunities and set priorities for cancer control interventions. 
Where possible, it is important to examine multiple indices and 
risk indicators at the national, state, and local level. In addition, 
although not always feasible in national reports, it is important to 
recognize that categorizing the population by broad racial and 
ethnic categories may mask important differences within and 
among populations.
We provided a comprehensive evaluation of the incidence and 
mortality for all primary (malignant and nonmalignant) brain and 
ONS tumors, as well as trends in incidence and survival on a 
national level. This report expands on the descriptive epidemiology 
of primary brain tumors presented by the Central Brain Tumor 
Registry of the United States in its annual statistical report (16). 
Collection of nonmalignant (benign or uncertain behavior) tumors 
began nationwide in diagnosis year 2004, allowing for 4 years of 
data (2004–2007) to be presented here. Nonmalignant tumors 
accounted for the majority of all brain tumors, representing two-
thirds of all adult and one-third of all childhood (aged 0–19 years) 
brain tumors. Capturing surveillance data on nonmalignant brain 
tumors has demonstrated that meningioma is the most common 
form of brain tumor in the United States. Differing patterns by 
race, sex, and age were seen for different types of malignant and 
nonmalignant brain tumors. Although the reasons for these differ-
ences have not been elucidated, they may prove important for 
discovering differences in the etiology of these diverse tumors.
An important finding of the current analysis is the relative 
stability of the long-term incidence trends of malignant tumors of 
the neuroepithelial tissue. During the 27-year (1980–2007) time 
period studied, an increase of 1.9% per year during 1980–1987 was 
counterbalanced by a decrease of 0.4% per year during the remain-
ing 20 years, resulting in nearly identical incidence rates at the 
beginning and end of the study. However, marked differences in 
trends were observed for histological groups within this category 
of tumors. As with many cancers, trends may be influenced by a 
number of factors, including changes in diagnostic techniques and 
changes in coding and classification. The introduction of com-
puted tomography scans in the 1970s and magnetic resonance 
imaging scans and stereotactic biopsy in the mid-1980s (59) has led 
to less invasive methods for diagnosing these tumors and contrib-
uted in part to fluctuations in the incidence rates over time. 
Revisions in the World Health Organization’s histological 
classification of ONS tumors and the ICD-O also occurred during 
the period of the study, along with changes in the multiple primary 
rules for malignant brain tumors and the introduction of multiple 
primary rules for nonmalignant brain tumors. Brain and ONS 
tumors have been particularly difficult to diagnose pathologically 
because they often are heterogeneous histologically, genetically, 
and therapeutically (17,60). However, progress in understanding 
the molecular pathogenesis of malignant gliomas has begun to 
allow for better classification of these tumors (61–63).
In contrast to tumors of neuroepithelial tissue, marked changes 
in the incidence of lymphomas of the brain have been observed, 
likely because of increases in AIDS-related lymphomas in the 
1980s, followed by decreases in AIDS-related lymphomas after the 
introduction of highly active antiretroviral therapy in the 1990s 
(64). The short time period for which data on nonmalignant brain 
tumors are available in the United States precluded analysis of 
temporal trends.
Modest improvements in survival for many types of brain and 
ONS tumors likely result from improvements in diagnostic and 
surgical techniques, radiotherapy, chemotherapy, biological 
therapy, and the use of multimodality therapy (65,66). Despite 
improvements in treatment, major prognostic factors include the 
histology of the tumor, whether complete surgical resection is 
achieved, and the age of the patient at diagnosis (66). Late effects 
of therapy for childhood brain tumors are substantial and include 
neurocognitive deficiencies, hormone deficits, growth impairment, 
second primary brain tumors, and ototoxicity related to platinum 
chemotherapy (67–69).
Several reviews of risk factors for brain tumors have been pub-
lished recently (70–78). The relatively low variation in incidence 
and death rates for cancer of the brain and ONS nationally and 
internationally suggests that environmental risk factors do not play 
a major role in this disease (70–74). In fact, other than hereditary 
tumor syndromes (17) and increased familial risk without a known 
syndrome (79–82), the only known modifiable causal risk factor for 
brain tumors is exposure to ionizing radiation (71–74,78). 
Variability in age at onset and molecular tumor characteristics 
suggests that risk factors for brain tumors may differ by histolog-
ical type (16,17,75,75–77). An example is the mostly consistent 
inverse association that has been observed between history of 
atopic disease, including allergies and asthma, and risk of glioma 
(72–74,83–97) and possibly meningioma (78,95–98); but no associ-
ation with nerve sheath tumors has been found (84).
Several reviews summarize studies evaluating exposure to cellular 
phones and the risk of brain tumors (78,99–102). Short-term (<10 
years) exposures to cellular telephones appear to have no association 
with risk of brain tumors. However, the association with long-term 
(>10 years) use remains unclear, primarily because of the relatively 
recent adoption of widespread use of cellular phones, as well as issues 
of bias and study design. Acoustic neuromas are of particular interest 
with regard to cellular phone use because of the proximity of these 
tumors to the phone. However, studies that have examined this asso-
ciation have mixed results and limited numbers of long-term users; 
further studies with longer term follow-up will be needed to evaluate 
whether there is an increased risk of acoustic neuromas associated 
with the use of cellular phones (99–102). A recent study using data 
from SEER 9 registries for 1977–2006 found decreasing or stable 
brain cancer incidence rate trends for whites in most age groups 
except among women aged 20–29 years in 1992–2006, which was 
driven by a rising incidence of frontal lobe cancers (103). We exam-
ined age- and sex-specific trends in overall malignant brain cancer 
incidence rates among whites in the SEER 13 registries from 1992 to 
2007 and NAACCR data for 1995–2007 (Supplementary Table 8, 
available online). Although the short time period for which non-
malignant data are available in the United States precludes analysis of 
temporal trends, the relatively large number of acoustic neuromas 
identified in the first 4 years of data collection suggests that etiologic 
studies will be possible in the future.
Limitations
High-quality cancer surveillance data now cover 93% of the US 
population for incidence and the entire population for mortality; 
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however, certain limitations in data sources, data collection, and 
analyses may have influenced the findings of this report. First, state 
and national population estimates are provided annually by the 
Census Bureau to estimate intercensal populations. Differences 
between the numerator (incidence data) and denominator (US 
Census population data) can occur in the designation of race and/
or ethnicity, place of residency, age, single vs multiple races, and 
the like. Every effort is made to ensure that the definition of the 
numerator and denominator are the same. Intercensal population 
estimates based on numbers updated by birth and death data are 
more subject to error than the estimates based on the actual count. 
Although these population estimates are believed to be the most 
accurate available, errors in the estimates may increase as time 
passes from the original recording of Census data. The NCI devel-
oped modifications to these Census estimates to attempt to 
account for changes in 2005 county-level populations because of 
displacement of people after Hurricanes Katrina and Rita in the 
most-affected counties of Louisiana, Mississippi, Alabama, and 
Texas. Censal and other data are used to classify the incidence 
cases, and census definitions are used to determine residency for 
the incidence cases. Race and ethnicity, however, generally are 
self-reported, but for the incidence cases, this information 
may come from a wider group of sources (patient, relative, nurse, 
doctor, coroner, funeral director). To enhance race and ethnicity, 
determination for the incidence cases, special studies and algo-
rithms are used. For example, a match of incidence cases to IHS 
rosters is undertaken to correct the possible underreporting of AI/
ANs, and NAACCR has developed guidelines and algorithms for 
enhancing Hispanic-Latino and API identification. Consistency 
over time in definitions for both census and incidence data is an 
issue, and efforts have been made to bridge single race and mul-
tiple race reporting (more information available on http://www. 
cdc.gov/nchs/nvss/bridged_race.htm). Second, joinpoint models 
were used to describe long-term (1992–2007) and short-term 
(1998–2007) trends. The AAPC, a summary measure of a trend 
over a prespecified fixed interval based on an underlying joinpoint 
model, was used to describe all trend data. The joinpoint model is 
preferable to single linear regression when a sufficient number of 
years are available for analysis because it enables identification of 
recent changes in magnitude and direction of trends. However, it 
may mask the underlying data and give an impression of a contin-
uous increase or decrease over time when this is not the case. In 
addition, although methods have been adapted recently to adjust 
for delayed reporting of aggregated data similar to earlier pub-
lished methods used for incidence from the nine oldest SEER 
registries (30), methods have not been tested on data from regis-
tries outside of SEER and were employed in our analysis only for 
SEER 9 and SEER 13. Delayed reporting may affect the most 
recent joinpoint segments, overestimating recent decreases and 
underestimating recent increases.
Third, US Department of Veterans Affairs (VA) hospitals tra-
ditionally have been a major source of data for cancers diagnosed 
among veterans, representing approximately 3%–8% of cancer 
diagnoses among men. A 2007 policy change regarding the trans-
fer of VA cancer data to state central cancer registries has resulted 
in incomplete reporting of VA hospital cases in some but not all 
state registries. This change has affected reporting from the third 
quarter of the 2004 diagnosis year through the current time 
period. As a result, cancer incidence rates among men for 2005–
2007 are thought to be underestimated by 0.8%–2% for all cancers 
combined, according to independent statistical analyses conducted 
by the CDC and SEER. The level of underreporting varied from 
0.5% to 4% according to cancer site, race, and age group (14,104). 
The amount of underestimation also may vary by local VA facility 
reporting patterns and the VA’s contribution to the total number 
of cancers. Progress in collecting VA data has been made in many 
states with the enactment of special data-sharing agreements with 
the VA. Over time, as cancer registries receive these missing VA 
cases, national cancer incidence estimates will be more complete 
and accurate.
Fourth, as routinely noted in the Annual Reports to the Nation 
(1–12), the broad racial and ethnic groups categorized for our 
analyses may mask variations in the cancer burden by country of 
origin; for example, Chinese and Vietnamese in the API group 
(105) and Cubans and Mexicans in the Hispanic group (9,106), or 
by other unique characteristics of high- or low-risk populations 
(107–110). Also, cancer rates for populations may be limited by 
difficulties in ascertaining race and ethnicity information from 
medical records, death certificates, and census reports (25).
Future Directions
The observed decreases in overall cancer incidence and death rates 
in nearly all racial and ethnic groups are highly encouraging. This 
progress could be accelerated by comprehensively applying existing 
cancer control knowledge of cancer prevention, early detection, 
and treatment to public health and clinical practices. Unfortunately, 
at this point in time, not all cancer sites are amenable to cancer 
control practices, and innovative methods to study these cancers 
and rare tumors must be developed. For example, the relative 
rarity of brain tumors, including many histological subtypes, has 
required investigators to establish consortia and pooled studies, 
especially for studies of genetic risk factors and gene–environment 
interaction (70,111–114). Many advances are being made in the 
molecular characterization of brain and ONS tumors and many 
other types of cancer. Tumor biospecimen banking linked with 
treatment and outcome information will be particularly important 
in studying the prognostic and predictive value of such markers 
and in developing targeted therapies (115–117) to improve effec-
tiveness, lessen toxicity, and measure response to therapy more 
quickly. It is too early to assess the impact of some treatment 
advances or the progress in targeted therapy that is expected to 
emerge in future years.
The US population aged 65 years and older is expected to 
double in size by 2030 (about 71 million persons) compared with 
the number reported in the 2000 census (118). Improvements in 
health and welfare also mean that individuals are expected to live 
longer, often with a range of health conditions that include the 
diagnosis of cancer. Even with declining cancer incidence rates, 
the absolute number of individuals diagnosed with cancer will 
continue to increase because of these population changes, leading 
to increased demand for cancer-related medical services through 
the spectrum of diagnosis, active treatment, and posttreatment 
medical management. Effective management of the cancer burden 
will require the application of sound cancer control strategies in 
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prevention, detection, treatment, and survivorship, as well as 
resources to provide good quality of care. Continued utilization of 
quality population-based data systems and translation of evidence-
based clinical and basic research findings to public health practices 
are essential to the development of public policies for cancer.
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